Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules.

Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JE, Lazareno S, Molloy JE, Birdsall NJ.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8. doi: 10.1073/pnas.0907915107. Epub 2010 Jan 20.

2.

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.

3.

Allosterism at muscarinic receptors: ligands and mechanisms.

Birdsall NJ, Lazareno S.

Mini Rev Med Chem. 2005 Jun;5(6):523-43. Review.

PMID:
15974931
4.
5.
6.

Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors.

Lazareno S, Popham A, Birdsall NJ.

J Mol Neurosci. 2003;20(3):363-7.

PMID:
14501021
7.

Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.

Tränkle C, Weyand O, Voigtländer U, Mynett A, Lazareno S, Birdsall NJ, Mohr K.

Mol Pharmacol. 2003 Jul;64(1):180-90.

PMID:
12815174
8.

Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors.

Lazareno S, Popham A, Birdsall NJ.

Mol Pharmacol. 2002 Dec;62(6):1492-505.

PMID:
12435818
9.

Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.

Lazareno S, Popham A, Birdsall NJ.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):123-7.

PMID:
12212769
10.

Substituted pentacyclic carbazolones as novel muscarinic allosteric agents: synthesis and structure-affinity and cooperativity relationships.

Gharagozloo P, Lazareno S, Miyauchi M, Popham A, Birdsall NJ.

J Med Chem. 2002 Mar 14;45(6):1259-74.

PMID:
11881995
11.

Quantification of receptor interactions using binding methods.

Lazareno S.

J Recept Signal Transduct Res. 2001 May-Aug;21(2-3):139-65. Review. No abstract available.

PMID:
11757681
12.

Multiple allosteric sites on muscarinic receptors.

Birdsall NJ, Lazareno S, Popham A, Saldanha J.

Life Sci. 2001 Apr 27;68(22-23):2517-24. Review.

PMID:
11392621
14.

Reply: effect of radioligand contamination on the analysis of homologous competition experiments

Lazareno S, Birdsall NJ.

Trends Pharmacol Sci. 2000 May;21(5):169. No abstract available.

PMID:
10785648
15.

Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor.

Leppik RA, Mynett A, Lazareno S, Birdsall NJ.

Mol Pharmacol. 2000 Mar;57(3):436-45.

PMID:
10692482
16.

Effects of contamination on radioligand binding parameters.

Lazareno S, Birdsall NJ.

Trends Pharmacol Sci. 2000 Feb;21(2):57-60.

PMID:
10664609
17.

Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies.

Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, Sugimoto M.

Mol Pharmacol. 1999 Apr;55(4):778-86.

PMID:
10101037
18.

Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.

Lazareno S, Birdsall B, Fukazawa T, Gharagozloo P, Hashimoto T, Kuwano H, Popham A, Sugimoto M, Birdsall NJ.

Life Sci. 1999;64(6-7):519-26.

PMID:
10069518
19.

Allosteric interactions of quaternary strychnine and brucine derivatives with muscarinic acetylcholine receptors.

Gharagozloo P, Lazareno S, Popham A, Birdsall NJ.

J Med Chem. 1999 Feb 11;42(3):438-45.

PMID:
9986715
20.

Measurement of agonist-stimulated [35S]GTP gamma S binding to cell membranes.

Lazareno S.

Methods Mol Biol. 1999;106:231-45. Review. No abstract available.

PMID:
9921508
21.

Muscarinic interactions of bisindolylmaleimide analogues.

Lazareno S, Popham A, Birdsall NJ.

Eur J Pharmacol. 1998 Nov 6;360(2-3):281-4.

PMID:
9851596
22.
23.

Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies.

Lazareno S, Gharagozloo P, Kuonen D, Popham A, Birdsall NJ.

Mol Pharmacol. 1998 Mar;53(3):573-89. Erratum in: Mol Pharmacol 1999 Jan;55(1):194.

PMID:
9495826
24.

To what extent can binding studies allow the quantification of affinity and efficacy?

Birdsall NJ, Lazareno S.

Ann N Y Acad Sci. 1997 May 30;812:41-7. Review. No abstract available.

PMID:
9186719
25.

Measurement of agonist-stimulated [35S]GTP gamma S binding to cell membranes.

Lazareno S.

Methods Mol Biol. 1997;83:107-16. Review. No abstract available.

PMID:
9210140
26.

Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes.

Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, Popham A, Sugimoto M.

Life Sci. 1997;60(13-14):1047-52. Review.

PMID:
9121346
27.

Quantitation of allosteric interactions.

Lazareno S, Birdsall N.

Trends Pharmacol Sci. 1996 Dec;17(12):443-4. No abstract available.

PMID:
9014497
28.

Stereoselective recognition of the enantiomers of phenglutarimide and of six related compounds by four muscarinic receptor subtypes.

Waelbroeck M, Lazareno S, Pfaff O, Friebe T, Tastenoy M, Mutschler E, Lambrecht G.

Br J Pharmacol. 1996 Dec;119(7):1319-30.

29.

The affinity of adenosine for the high- and low-affinity states of the human adenosine A1 receptor.

Cohen FR, Lazareno S, Birdsall NJ.

Eur J Pharmacol. 1996 Aug 1;309(1):111-4.

PMID:
8864701
30.

The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.

Cohen FR, Lazareno S, Birdsall NJ.

Br J Pharmacol. 1996 Apr;117(7):1521-9.

31.

Allosteric regulation of muscarinic receptors.

Birdsall NJ, Lazareno S, Matsui H.

Prog Brain Res. 1996;109:147-51. Review. No abstract available.

PMID:
9009701
33.

Allosteric regulation of G-protein-linked receptors.

Birdsall NJ, Cohen F, Lazareno S, Matsui H.

Biochem Soc Trans. 1995 Feb;23(1):108-11. Review. No abstract available.

PMID:
7758667
34.

Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.

Matsui H, Lazareno S, Birdsall NJ.

Mol Pharmacol. 1995 Jan;47(1):88-98.

PMID:
7838137
37.
39.

Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells.

Lazareno S, Buckley NJ, Roberts FF.

Mol Pharmacol. 1990 Dec;38(6):805-15.

PMID:
2250662
40.

Functional and binding studies with muscarinic M2-subtype selective antagonists.

Lazareno S, Roberts FF.

Br J Pharmacol. 1989 Sep;98(1):309-17.

41.

Cholinergic treatments for Alzheimer's disease.

Roberts F, Lazareno S.

Biochem Soc Trans. 1989 Feb;17(1):76-9. Review. No abstract available.

PMID:
2653922
42.
43.

Pirenzepine indicates heterogeneity of muscarinic receptors linked to cerebral inositol phospholipid metabolism.

Lazareno S, Kendall DA, Nahorski SR.

Neuropharmacology. 1985 Jun;24(6):593-5.

PMID:
3839571
44.

Effect of lead exposure on dopaminergic D2 receptor binding in the 21-day-old rat.

Winder C, Lazareno S.

Toxicol Lett. 1985 Feb-Mar;24(2-3):209-14.

PMID:
3157243
45.
46.
47.

d-Amphetamine and punished responding: the role of catecholamines and anorexia.

Lazareno S.

Psychopharmacology (Berl). 1979 Nov;66(2):133-42.

PMID:
43548

Supplemental Content

Loading ...
Support Center